AKT1 and renal cell carcinoma: Therefore, pharmacological and genetic inhibition of the PI3K/AKT signaling pathway has been demonstrated to attenuate RCC migration and invasion, highlighting its therapeutic relevance, such as PI3K inhibitor treatment reduces RCC progression (Khalid et al., 2023).